Abstract
The relationship between antibronchospasmic, tachycardiac, or hypokalaemic effects and plasma concentration of L-isoproterenol (ISP) hydrochloride was investigated in guinea-pigs in vivo. ISP was infused at the rate of 10, 30, 50, 100, and 300 ng kg-1 min-1. The antibronchospasmic effect was expressed as the attenuation of methacholine-induced bronchospasm. The EC50 values of ISP for antibronchospasmic and tachycardiac effects were 5.12 nM and 3.95 nM, respectively. Although they were comparable to the values reported in vitro (7.23-0.358 nM, 1.77 nM), the concentration response relationship of ISP for antibronchospasmic effect was quite steep with a slope factor of more than six. Moreover, a decrease in plasma potassium level was not clearly detected. The experimental procedure in our present study was useful for evaluating antibronchospasmic and tachycardiac effects of beta-agonists.
| Original language | English |
|---|---|
| Pages (from-to) | 745-753 |
| Number of pages | 9 |
| Journal | Biopharmaceutics and Drug Disposition |
| Volume | 16 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 1995 |
| Externally published | Yes |
Fingerprint
Keywords
- Guinea-pigs
- Heart rate
- Isoproterenol
- Methacholine chloride
- Pharmacodynamics
- Potassium
- Pulmonary function
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology, Toxicology and Pharmaceutics(all)
Cite this
Antibronchospasmic, tachycardiac, and hypokalaemic effects of L-isoproterenol in guinea-pigs. / Ohtani, Hisakazu; Yamamoto, K.; Sawada, Y.; Iga, T.
In: Biopharmaceutics and Drug Disposition, Vol. 16, No. 9, 1995, p. 745-753.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Antibronchospasmic, tachycardiac, and hypokalaemic effects of L-isoproterenol in guinea-pigs
AU - Ohtani, Hisakazu
AU - Yamamoto, K.
AU - Sawada, Y.
AU - Iga, T.
PY - 1995
Y1 - 1995
N2 - The relationship between antibronchospasmic, tachycardiac, or hypokalaemic effects and plasma concentration of L-isoproterenol (ISP) hydrochloride was investigated in guinea-pigs in vivo. ISP was infused at the rate of 10, 30, 50, 100, and 300 ng kg-1 min-1. The antibronchospasmic effect was expressed as the attenuation of methacholine-induced bronchospasm. The EC50 values of ISP for antibronchospasmic and tachycardiac effects were 5.12 nM and 3.95 nM, respectively. Although they were comparable to the values reported in vitro (7.23-0.358 nM, 1.77 nM), the concentration response relationship of ISP for antibronchospasmic effect was quite steep with a slope factor of more than six. Moreover, a decrease in plasma potassium level was not clearly detected. The experimental procedure in our present study was useful for evaluating antibronchospasmic and tachycardiac effects of beta-agonists.
AB - The relationship between antibronchospasmic, tachycardiac, or hypokalaemic effects and plasma concentration of L-isoproterenol (ISP) hydrochloride was investigated in guinea-pigs in vivo. ISP was infused at the rate of 10, 30, 50, 100, and 300 ng kg-1 min-1. The antibronchospasmic effect was expressed as the attenuation of methacholine-induced bronchospasm. The EC50 values of ISP for antibronchospasmic and tachycardiac effects were 5.12 nM and 3.95 nM, respectively. Although they were comparable to the values reported in vitro (7.23-0.358 nM, 1.77 nM), the concentration response relationship of ISP for antibronchospasmic effect was quite steep with a slope factor of more than six. Moreover, a decrease in plasma potassium level was not clearly detected. The experimental procedure in our present study was useful for evaluating antibronchospasmic and tachycardiac effects of beta-agonists.
KW - Guinea-pigs
KW - Heart rate
KW - Isoproterenol
KW - Methacholine chloride
KW - Pharmacodynamics
KW - Potassium
KW - Pulmonary function
UR - http://www.scopus.com/inward/record.url?scp=0028884825&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028884825&partnerID=8YFLogxK
U2 - 10.1002/bdd.2510160905
DO - 10.1002/bdd.2510160905
M3 - Article
VL - 16
SP - 745
EP - 753
JO - Biopharmaceutics and Drug Disposition
JF - Biopharmaceutics and Drug Disposition
SN - 0142-2782
IS - 9
ER -